XyloCor Therapeutics is a biopharmaceutical company focused on developing gene therapy for advanced coronary artery disease.

XyloCor Therapeutics

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Sofinnova Investments

Fountain Healthcare Partners

EQT life science

Longwood Fund

Lumira Ventures

XyloCor Therapeutics, Inc.

Today our CEO Al Gianchetti was interviewed by Ali Gorman of BiotechTV and they discussed the exciting progress XyloCor is making with the clinical development of XC001 for patients with refractory angina. In addition, they discussed XyloCor's recent agreement with SmartCella which enables XyloCor to use their Extroducer catheter (use the title from the press release) to deliver XC001 to the heart without the need for a surgical procedure. 
#Philly #biotech #cardiovascular #genetherapy
https://lnkd.in/g_ADHVMV

#NEWS: Today, we announced an agreement with Smartwise , a unit of SmartCella Holding AB (“SmartCella”). We have entered into a licensing agreement under which XyloCor has rights to the Extroducer® Infusion Catheter System ®, a first-in-class endovascular device designed to deliver advanced therapies directly into the heart [and hard-to-reach tissues]. XyloCor plans to deploy the Extroducer to support catheter-based endocardial delivery of its lead gene therapy candidate, XC001 (encoberminogene rezmadenovec), in future clinical studies and commercial use. 
Read more here: https://lnkd.in/edyPaxJy   
 #GeneTherapy #HeartDisease #Innovation #cardiovascular

Thank you to Laurie Glimcher, Ivana Magovcevic-Liebisch, PhD, JD, Maria Whitman, Al Gianchetti & Brian Alexander for the important #patientcentricity discussion #longwoodhealthcareleaders Longwood Fund

#NEWS: Today, we announced positive Phase 2 data for our refractory angina treatment candidate, a novel therapeutic approach that aims to fill a significant unmet medical need for people who have exhausted available treatment options and have a debilitating quality-of-life. Our #clinicaltrial results were also presented today at the  Society for Cardiovascular Angiography & Interventions 2024 Scientific Sessions and will be published in the medical journal Circulation: Cardiovascular Interventions. Read more here: https://lnkd.in/edyPaxJy  
#SCAI2024
 #GeneTherapy #HeartDisease #Innovation

Happy Holidays from the XyloCor family to yours.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 4, 2024 5:29 AM	77edcb3b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 5:35 AM	51e715f6
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	8b8bbb41
crunchbase profile	general
li profile	general	Sep 4, 2024 5:29 AM	20ff16c0
translate crunchbase fundingrounds	general
peers	general	Sep 4, 2024 5:29 AM	673a921e
news basic	general	Sep 4, 2024 5:29 AM	1d74eb2d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

XYLO

COM:XYLOCOR

XyloCor Therapeutics